The Association Between CYP2C19 Genotype and Phenotype and the Impact on 1-Year Outcomes Following Phenotype Guided-escalated Antiplatelet Therapy in Myocardial Infarction Patients with Drug Eluting Stents

Background: Clopidogrel high on-treatment platelet reactivity(HPR) is an independent predictor of major adverse cardiovascular events(MACE) in myocardial infarction(MI) patients with drug eluting stents(DES). Despite published guidelines in which more potent ticagrelor, is preferred, clopidogrel remains the treatment choice in Malaysia due to cost reason. The use of point-of-care(POC) instruments in phenotype-guided escalated therapy (GES) could be explored.